Curis Announces Appointment of Kenneth Pienta, M.D. to Board of Directors
Brings Over 20 Years of Experience in Oncology Clinical Practice and Cancer
Research With Expertise in Precision Approaches to Cancer Therapies
LEXINGTON, Mass., March 11, 2013 (GLOBE NEWSWIRE) -- Curis, Inc.
(Nasdaq:CRIS), an oncology-focused company seeking to develop next generation
targeted drug candidates for cancer treatment, today announced the appointment
of Kenneth Pienta, M.D. to its Board of Directors. Dr. Pienta currently serves
as the Donald S. Coffey Professor of Urology, Professor of Oncology, and
Pharmacology and Molecular Sciences at the Johns Hopkins University School of
"We believe that Ken will add further scientific depth to the Curis Board and
will continue to make important contributions to Curis due to his deep
experience in oncology patient care as well as his unique understanding of
precision therapeutic approaches to cancer treatment," said Chief Executive
Officer Dan Passeri. "We have benefited from Ken's deep experience in his role
as the head of our clinical and scientific advisory board and an advisor in
other strategic matters, and we are delighted to welcome him to our board."
"I am pleased to join the Curis board and look forward to working with the
board and management team as we collectively seek to advance Curis towards
becoming a leading oncology development company," said Dr. Pienta.
Prior to his appointment at the Johns Hopkins University School of Medicine,
Dr. Pienta served as the Associate Vice President for Research, Health
Sciences, for the University of Michigan and as the Director of Precision
Medicine for the Michigan Center for Translational Pathology from 2008 to
From 1995 to 2013, Dr. Pienta served as the Director of the Prostate
Specialized Program of Research Excellence (SPORE) at The University of
Michigan. In this role, Dr. Pienta created a proven, peer-reviewed track
record in organizing and administering a translational research program that
successfully incorporated bench research, drug candidate development and
clinical application. Dr. Pienta has international expertise in the
development of novel chemotherapeutic programs for cancer and has championed
the concept that translational research is often best accomplished by
multi-disciplinary teams of scientists and clinicians.
Dr. Pienta is a two-time American Cancer Society Clinical Research Professor
Award recipient, is the author of more than 350 peer-reviewed articles and has
been the principal investigator on numerous local and national clinical
trials. Dr. Pienta currently serves as the Director of Research for the Brady
Urological Institute and is also involved in research to define the tumor
microenvironment of cancer metastases, as well as developing new therapies for
About Curis, Inc.
Curis is an oncology-focused company seeking to develop and commercialize next
generation targeted drug candidates for cancer treatment. Erivedge® is the
first and only FDA-approved medicine for the treatment of advanced basal cell
carcinoma and is being commercialized and developed by Roche and Genentech, a
member of the Roche Group, under a collaboration agreement between Curis and
Genentech. Curis is also developing its pipeline of proprietary targeted
cancer drug candidates, including CUDC-427, a small molecule antagonist of IAP
proteins; CUDC-907, a dual PI3K and HDAC inhibitor; and CUDC-101, an EGFR/HER2
and HDAC inhibitor. For more information, visit Curis' website at
The Curis, Inc. logo is available at
This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, including without
limitation statements regarding the expected benefits of the Company's
appointment of Dr. Pienta to serve as a member of its board of directors.
Forward-looking statements used in this press release may contain the words
"believes," "expects," "anticipates," "plans," "seeks," "estimates,"
"assumes," "will," "may," "could" or similar expressions. These
forward-looking statements are not guarantees of future performance and
involve risks, uncertainties, assumptions and other important factors that may
cause actual results to be materially different from those indicated by such
forward-looking statements, including without limitation the risk factors
described by the Company in its Quarterly Report on Form 10-Q for the year
ended September 30, 2012 and other filings that it periodically makes with the
Securities and Exchange Commission.
In addition, any forward-looking statements represent the views of Curis only
as of today and should not be relied upon as representing Curis' views as of
any subsequent date. Curis disclaims any intention or obligation to update any
of the forward-looking statements after the date of this press release whether
as a result of new information, future events or otherwise.
CONTACT: Michael P. Gray
Chief Financial Officer
Curis, Inc. Logo
Press spacebar to pause and continue. Press esc to stop.